UNASSIGNED: e11133 Background: @entity0 ( @entity0 ) is a rare and aggressive form of invasive @entity0 accounting for 3-6% of all cases. @entity0 @entity1 have higher rates of distant recurrence. We hypothesized that circulating @entity5 cells (CTCs) can be identified in @entity1 with IBCs and may correlate with @entity5 characteristics. METHODS: All @entity1 had blood samples taken at the time of primary surgery. CTCs (per 7.5 ml blood) were detected using the Cell Search system (Veridex) and were defined as nucleated cells lacking @entity1195 but expressing cytokeratins (CK) 8, 18, or 19. The presence of >=  1 epithelial cells meeting morphologic criteria for @entity5 was considered a positive result. Statistical analyses used Chi square and @entity16043 's exact tests. RESULTS: We prospectively evaluated 38 @entity0 @entity1 enrolled in an IRB approved protocol undergoing surgery for stage I-III @entity0 . Median follow-up was 27 months and mean age was 51 years. Eleven @entity1 (29%) were ER +ve, 10 (26%) were PR +ve and 18 (47%) were @entity1722 positive. Thirty four @entity1 (94%) had positive lymph nodes (LNs) at presentation, 29 (78%) had high-grade @entity5 and 19 (54%) had @entity3 . IBCs were more likely to be high grade (P<0.0001), ER -ve (P<0.0001), PR -ve (P<0.0001), @entity1722 +ve (P<0.0001), High Ki-67 (P= 0.005) and have a BMI > 25kg/m(2) (P=0.04). Ten (30%) @entity1 were CTC positive. CTCs were more likely be found in @entity1722 +ve (8/16; 50%) vs. @entity1722 -ve @entity5 (2/17; 12%) [OR= 7.5; 95% C.I. = 1.05-83.4; P= 0.026]. No statistically significant correlations were observed between @entity5 characteristics (ER, PR, LNs, high grade) and presence of CTCs. CONCLUSIONS: Approximately, one-third of @entity0 @entity1 had CTCs at the time of primary surgery. @entity1722 overexpression predicted the presence of CTCs in these @entity1 . Further study with longer follow up is needed to determine if CTCs predicted relapse in this cohort.

Use of XXXX amplification in the @entity5 to predict presence of circulating @entity5 cells in @entity0 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'Inflammatory breast cancer', 'IBC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'primary tumor', 'malignancy', 'tumors'] @entity1195 :: ('5788', 'Gene') :: ['CD45'] @entity3 :: ('MESH:D009362', 'Disease') :: ['lymphovascular invasion'] @entity16043 :: ('76720', 'Species') :: ['Fisher'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity1722 :: (2064,Gene) :: ['HER2']
